home / stock / lgvn / lgvn quote
Last: | $1.29 |
---|---|
Change Percent: | -0.75% |
Open: | $1.35 |
Close: | $1.29 |
High: | $1.3504 |
Low: | $1.27 |
Volume: | 326,488 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.29 | $1.35 | $1.29 | $1.3504 | $1.27 | 326,488 | 05-16-2024 |
$1.34 | $1.42 | $1.34 | $1.49 | $1.29 | 494,286 | 05-15-2024 |
$1.39 | $1.28 | $1.39 | $1.58 | $1.28 | 691,470 | 05-14-2024 |
$1.3 | $1.45 | $1.3 | $1.48 | $1.24 | 492,190 | 05-13-2024 |
$1.455 | $1.59 | $1.455 | $1.59 | $1.43 | 300,439 | 05-10-2024 |
$1.54 | $1.67 | $1.54 | $1.6793 | $1.515 | 345,641 | 05-09-2024 |
$1.66 | $1.71 | $1.66 | $1.71 | $1.6 | 229,764 | 05-08-2024 |
$1.68 | $1.67 | $1.68 | $1.73 | $1.65 | 355,785 | 05-07-2024 |
$1.68 | $1.77 | $1.68 | $1.7708 | $1.66 | 287,538 | 05-06-2024 |
$1.75 | $1.81 | $1.75 | $1.88 | $1.73 | 395,492 | 05-03-2024 |
$1.81 | $1.78 | $1.81 | $2.0799 | $1.7 | 1,699,644 | 05-02-2024 |
$1.74 | $1.74 | $1.74 | $1.82 | $1.69 | 136,996 | 05-01-2024 |
$1.71 | $1.67 | $1.71 | $1.8 | $1.64 | 206,497 | 04-30-2024 |
$1.69 | $1.75 | $1.69 | $1.75 | $1.6 | 166,770 | 04-29-2024 |
$1.75 | $1.67 | $1.75 | $1.7899 | $1.6202 | 373,405 | 04-26-2024 |
$1.67 | $1.72 | $1.67 | $1.7201 | $1.6 | 322,087 | 04-25-2024 |
$1.72 | $1.83 | $1.72 | $1.83 | $1.68 | 303,471 | 04-24-2024 |
$1.82 | $1.91 | $1.82 | $1.92 | $1.76 | 271,924 | 04-23-2024 |
$1.87 | $1.98 | $1.87 | $2.06 | $1.81 | 485,013 | 04-22-2024 |
$1.92 | $1.92 | $1.92 | $2.1 | $1.9 | 459,014 | 04-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Longeveron Inc. Company Name:
LGVN Stock Symbol:
NASDAQ Market:
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board...